NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PRME

Prime Medicine Inc

Jul 03 • 04:00PM ET

3.11

Dollar change +0.04
Percentage change 1.30	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: ARKG IWM VTI IWN VXF IBB SCHA IWC VTWO GNOM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.66	Insider Own	60.65%	Shs Outstand	131.16M	Perf Week	17.36%
Market Cap	408.33M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.41%	Shs Float	51.66M	Perf Month	133.83%
Enterprise Value	385.22M	PEG	-	EPS next Q	-0.36	Inst Own	28.99%	Short Float	35.77%	Perf Quarter	73.74%
Income	-202.01M	P/S	106.06	EPS this Y	23.33%	Inst Trans	-6.35%	Short Ratio	7.33	Perf Half Y	11.87%
Sales	3.85M	P/B	3.81	EPS next Y	20.83%	ROA	-63.17%	Short Interest	18.48M	Perf YTD	6.51%
Book/sh	0.82	P/C	2.83	EPS next 5Y	18.30%	ROE	-115.21%	52W High	6.75 -53.93%	Perf Year	-43.25%
Cash/sh	1.10	P/FCF	-	EPS past 3/5Y	4.95% -124.13%	ROIC	-91.32%	52W Low	1.11 180.18%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-69.34%	Volatility	18.19% 14.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	100.06	EPS Y/Y TTM	22.37%	Oper. Margin	-5369.68%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	Sep 10, 2019	Quick Ratio	4.78	Sales Y/Y TTM	550.76%	Profit Margin	-5252.50%	RSI (14)	79.25	Recom	1.73
Dividend Gr. 3/5Y	- -	Current Ratio	4.78	EPS Q/Q	9.47%	SMA20	50.99%	Beta	2.27	Target Price	7.69
Payout	-	Debt/Eq	1.13	Sales Q/Q	146.02%	SMA50	86.34%	Rel Volume	1.47	Prev Close	3.07
Employees	214	LT Debt/Eq	1.07	Earnings	May 08 BMO	SMA200	18.93%	Avg Volume	2.52M	Price	3.11
IPO	Oct 20, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.59% -67.90%	Trades		Volume	3,699,410	Change	1.30%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Loading…
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Loading…
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Loading…
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 08:00AM	Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences (GlobeNewswire) +10.00%
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
Sep-19-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-07-23 04:01PM	Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.66%
Jul-25-23 07:45AM	2 Cathie Wood Stocks That Could Be Hidden Gems (Motley Fool)
Jun-29-23 08:46AM	We're Hopeful That Prime Medicine (NASDAQ:PRME) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-23 08:00AM	Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome (GlobeNewswire)
Jun-02-23 10:15AM	Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought (Motley Fool) +9.15%
May-31-23 08:00AM	Prime Medicine to Present at Investor Conferences in June (GlobeNewswire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Liu David R.	10% Owner	Jun 30 '25	Buy	2.52	21,000	52,830	20,240,945	Jul 01 04:03 PM
Liu David R.	10% Owner	Jun 23 '25	Buy	2.16	21,000	45,402	20,219,945	Jun 23 04:33 PM
Liu David R.	10% Owner	Jun 16 '25	Buy	1.49	21,000	31,196	20,198,945	Jun 16 05:14 PM
Liu David R.	10% Owner	Jun 11 '25	Buy	1.60	21,000	33,590	20,177,945	Jun 12 04:49 PM
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22 04:22 PM
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22 04:21 PM
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRME

Prime Medicine Inc

Upgrade your FINVIZ experience